AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01190995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The patient will be enrolled into the study only after an informed written consent has been obtained from either of the parent/caregiver. At the beginning of each potentially painful procedure namely, venepuncture, venous and arterial cannulation, heel lance,orogastric tube insertion, suprapubic aspiration of urine and any other skin breaking procedure,0.5ml of solution marked with patients serial number will be administered by a prefilled syringe to the patient on the anterior aspect of the tongue , avoiding spillage , by the personnel carrying out the procedure
Study NCT00884806 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FID 114675A Multi-Purpose Disinfecting Solution (MPDS)
Description: Investigational solution intended for use as a cleaning, rinsing, conditioning, disinfecting, and storage solution for silicone hydrogel (SiH) contact lenses
Study NCT00411411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Januvia
Description: 200 mg t.i.d
Study NCT00411411 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03038854 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test GUM
Description: Growing up milks (GUMs) are milk-based drinks with vitamins and minerals for toddlers and pre-school children.
Study NCT03038854 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard GUM
Description: Growing up milks (GUMs) are milk-based drinks with vitamins and minerals for toddlers and pre-school children.
Study NCT00884806 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Etafilcon A contact lens (ACUVUE® 2™)
Description: Commercially marketed hydrogel contact lens for daily wear use
Study NCT02916563 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood Glucose Monitoring System Altitude Performance
Description: Performance as assessed against a reference method at an altitude of approximately 10,000 feet.
Study NCT00884806 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Senofilcon A contact lens (ACUVUE® OASYS™)
Description: Commercially marketed silicone hydrogel contact lens for daily wear use
Study NCT00884806 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotrafilcon B contact lens (O2 OPTIX®)
Description: Commercially marketed silicone hydrogel contact lens for daily wear use
Study NCT00884806 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balafilcon A contact lens (PureVision®)
Description: Commercially marketed silicone hydrogel contact lens for daily wear use
Study NCT04044885 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nap
Description: Looking at the difference between continuous sleep opportunities and split-sleep opportunities.
Study NCT01692652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical loteprednol etabonate (lotemax 0.5%) with warm compress & ocular massage
Study NCT01692652 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: warm compress only group
Study NCT01502241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 100 mg/m2 per day on seven out of fourteen days.
Study NCT01502241 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy of the partial brain.
Description: 60 Gy in 30 fractions à 2 Gy.
Study NCT00091676 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FNHLId1
Description: 5 monthly vaccinations over a 6 month time period consisting of 0.5 mg ID-KLH s.c. on day 1 and 100 mcg/m²/day GM-CSF s.c. on days 1-4
Study NCT00091676 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: KLH + GM-CSF
Description: 5 monthly vaccinations at month 1, 2, 3, 4, and 6 consisting of 0.5 mg KLH s.c on day 1 and 100 mcg/m²/day GM-CSF s.c. on days 1-4
Study NCT00629447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Innohep
Description: The patients will receive a single daily subcutaneous injection of Tinzaparin at 4500 IU.
Study NCT00880724 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: IBV Valve
Description: Placement of IBV Valve in the airways of treatment subjects. Bronchoscopic procedure in control group.
Study NCT04034732 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Relapses Prevention (MBRP)
Description: Manualized MBRP program is used with a central theme in each session, with meditation practices and relapse prevention exercises and discussions. Themes include the concept of automatic pilot and its relationship to addiction relapse, recognizing thoughts and emotions in relation to triggers of relapse, integrating mindfulness practices into daily activities, practicing mindfulness in high risk situations and the role of thoughts and emotions in relapse. Include daily homework exercises that consist of awareness exercises directed at increasing non-judgmental awareness of bodily sensations, thoughts and feelings, together with exercises designed to integrate awareness skills into daily life. Include training in mindfulness through body scan, sitting meditation, and mindful stretching exercises, to cultivate awareness during simple stretching movement.
Study NCT03038854 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cows' milk
Description: Homogenized store-bought full fat cow's milk.
Study NCT00958932 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech recognition
Description: The TEAM intervention is a program to increase communication with families, provide feedback to families about their refill adherence, assess asthma symptoms, deliver health communication messages, encourage parents to ask questions of asthma care managers, and facilitate refilling ICS prescription. Speech recognition calls will be tailored to specific situations including new or re-issued ICS prescriptions, failure to fill an initial prescription, failure to refill, or failure to refill following an ED visit, hospitalization, or oral steroid burst resulting from an asthma exacerbation.
Study NCT03765203 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Natera KidneyScan
Description: Online educational materials on Natera Kidneyscan (dd-cfDNA) and sample test results for simulated patients
Study NCT03765203 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Performance and Value Vignettes
Description: Online renal allograft simulated patients
Study NCT03765203 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Performance and Value Vignettes
Description: Online renal allograft simulated patients
Study NCT03003507 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Enteral Formula With Fructose
Description: Low-carbohydrate Enteral Formula With Fructose
Study NCT03003507 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Enteral Formula Without Fructose
Description: Low-carbohydrate Enteral Formula Without Fructose
Study NCT04028466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Patients will be randomized to receiving vonoprazan 20mg tablet or omeprazole 40mg capsule, either of which will be taken 30 minutes before the first meal of the day for 14 days
Study NCT04028466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: Patients will be randomized to receving vonoprazan 20mg tablet or omeprazole 40mg capsule, either of which will be taken 30 minutes before the first meal of the day for 14 days
Study NCT00875342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCS
Description: 1. Cognitive behavioral treatment with exposure therapy plus D-Cycloserine (100 mg on days of therapy session (approximately 9 times)
Study NCT00875342 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2. Cognitive behavioral treatment with exposure therapy plus a placebo(sugar pill) (Placebo given on days of therapy session (9 times)
Study NCT01970059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-Release Carvedilol Sulfate
Study NCT01970059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sustained-release Metoprolol Succinate
Study NCT05204433 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT04034732 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Control
Description: Participants in the UCCG condition will remain in their standard outpatient aftercare provided by the treatment agency with an aim to maintain their abstinence with the help from social workers or other healthcare professionals through different activities, such as topics on life training skills such as rational thinking skills, grief and loss, assertiveness, self esteem, goal setting, effects of drugs on interpersonal relationships and experience. Frequency of their visits to / contacts with healthcare professionals will be recorded.
Study NCT01420822 — intervention group
Intervention type: DRUG
Intervention: Fluticasone
Description: Collection of safety data
Study NCT02882100 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adjuvanted trivalent influenza vaccine
Description: Nursing home residents over 65 years are allocated to receive adjuvanted trivalent vaccine. Residents under 65 years are provided standard trivalent vaccine (TIV-Fluvirin).
Study NCT02882100 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: trivalent influenza vaccine
Description: Nursing home residents are allocated to receive standard trivalent vaccine (TIV).
Study NCT02882100 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trivalent influenza vaccine
Description: Nursing home residents are allocated to receive standard trivalent vaccine (TIV).
Study NCT01406015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: 50 mg once daily for 6 weeks.
Study NCT01406015 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-matching spironolactone once daily for 6 weeks.
Study NCT01508845 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol
Description: 800 IU vitamin D3, 1 dose; 800 IU deuterated vitamin D3, 1 dose
Study NCT01508845 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol
Description: 50,000 IU vitamin D3, 1 dose; 800 IU deuterated vitamin D3, 1 dose
Study NCT01508845 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol
Description: 50,000 IU vitamin D3, 1 dose; 800 IU vitamin D3, 1 dose
Study NCT01896583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP7147
Description: 300 mg, tablet, twice per day for 4 weeks oral
Study NCT01896583 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01656070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral cholecalciferol 1000000 UI (vitamin D3)
Study NCT01656070 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00733941 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High frequency training
Description: 24 training sessions, 8x weekly, followed by detraining phase 8 weeks, and retraining
Study NCT00733941 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: normal frequence training
Description: 24 training sessions, 3x weekly, followed by detraining phase 8 weeks, and retraining
Study NCT00678834 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: To surgery patients, Tocopherol capsules.
Description: 200mg (2 100mg capsules) to take by mouth twice daily to total 400mg daily
Study NCT00678834 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Tocotrienol to healthy subjects.
Description: 200 mg to take orally two times a day (400 mg a day).
Study NCT00678834 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: To surgery patients, Tocotrienol capsules.
Description: 200mg (2 100mg capsules) to take by mouth twice daily to total 400mg daily
Study NCT04382417 — intervention group
Intervention type: OTHER
Intervention: Observational study
Description: Not required
Study NCT01423734 — intervention group
Intervention type: OTHER
Intervention: magnetic resonance imaging (MRI)
Description: Each patient will undergo clinical and research MRI examinations. Before any MRI examination, the patient will answer a standard radiology MR department questionnaire form, with specific questions addressing contra-indications to MRI. The questionnaire form will be reviewed by radiology personnel as per standard practice.~During the research MRI, the patient will be monitored visually and communication will be maintained between the patient and the MR technologists via a speaker system. At the termination of the study, the patient will be evaluated by the MR department radiology personnel as done routinely. Two breath hold DWI sequences will be performed for each patient. Since this is a reproducibility study, identical scan parameters will be used for the clinical and research MRI. The multiple b value DWI will be performed using the enhanced DW sequence that have been recently made available on our 3.0 Tesla MR 750 scanners at the Breast and Imaging Center.
Study NCT02335424 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: IV infusion
Study NCT00624754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol/Budesonide
Description: Budesonide/Formoterol 400/12: 800 µg b.i.d for 1 month
Study NCT00624754 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lactose
Description: Lactose 2 puffs b.i.d for 1 month
Study NCT03891368 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Learning Collaborative
Description: InSHAPE teams consisting of health mentors, supervisors, and senior leaders from each mental health agency randomized to the VLC will be invited to attend an in-person initial kick-off meeting followed by once per month 90-minute VLC sessions. The VLC is organized into three stages: Prework, Action, and Continuous Improvement. VLC faculty, including interventionists with expertise in implementation science, quality improvement, and subject matter (i.e., InSHAPE) experts, will facilitate VLC sessions following a structured protocol to standardize the planning and execution of the VLC across three cohorts enrolled in the study.
Study NCT03891368 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Technical Assistance
Description: Scheduled calls will occur at 1 month, 2 months, 8 months, and 14 months following their participation in initial InSHAPE training following randomization and follow a structured protocol. At the end of each scheduled conference call, the coach will schedule the next call with the site.
Study NCT01141478 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Proton Beam Radiotherapy
Description: Fifteen consecutive sessions
Study NCT00703885 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.25 mg alprazolam
Description: 0.25 mg alprazolam PO (liquid) to be administered 1 hour prior to fMRI scan~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart.
Study NCT00703885 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1.0 mg alprazolam
Description: 1 mg alprazolam PO (liquid) will be administered 1 hour prior to fMRI scan~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart.
Study NCT03816878 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 pISV
Description: Administered as an intramuscular (IM) injection
Study NCT04105699 — intervention group
Intervention type: DEVICE
Intervention: Blood sampling
Description: Daily blood sample which will be taken for the PSP measurement using the abioSCOPE as well as another daily sample taken for central analysis of biomarkers of inflammation, infection and/or sepsis (including but not limited to C-reactive protein \[CRP\] and Procalcitonin \[PCT\]).
Study NCT03595007 — intervention group
Intervention type: BEHAVIORAL
Intervention: Kids Kicking Cancer program
Description: Individual instruction on how to lower stress and life challenges. Patient and martial artist will work together to identify obstacles that interfere with methadone goal reduction. Training will include learning certain martial arts rituals and breathing techniques. Patients will receive audio meditations for smart phone devices and regular reminders to practice. Each weekly meeting will be supplemented by 3 phone calls per week from the martial artist to support the training. Additionally a virtual reality device will be used to help lower stress.
Study NCT03847545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fampridine
Description: sustained-release tablet 10 mg morning and evening.
Study NCT00590759 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: GORE TAG® Thoracic Endoprosthesis
Description: implant
Study NCT02802111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol
Description: Patient receives albuterol 5 mg aerosolized. Oxygen consumption and vital signs are measured for 1 hour after intervention.
Study NCT02802111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levalbuterol
Description: Patient receives levalbuterol 2.5 mg aerosolized. Oxygen consumption and vital signs are measured for 1 hour after intervention
Study NCT01166191 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy
Study NCT01230359 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pyridoxine hydrochloride
Description: 2.5 grams per day for subjects weighing upto 27 kilos and 5 g per day for greater than 27 kgs for 12 weeks
Study NCT01230359 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Tang orange powder
Description: 2.5 grams per day for subjects weighing upto 27 kilos and 5 g per day for greater than 27 kgs for 12 weeks
Study NCT02584660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Participants will receive Rivaroxaban 15 milligram (mg) twice daily up to Days 21 by orally and Rivaroxaban 20 mg once daily up to Days 90 by orally.
Study NCT03956407 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive peripheral nerve stimulation
Description: Active repetitive peripheral nerve stimulation will be applied to the median nerve of the affected forearm with surface electrodes. The stimulator will be set to deliver bursts of 10 Hz stimulation at 50% duty cycle (500 ms on and off). For active stimulation, intensities will be set at the highest intensity able to induce sensory paraesthesias without overt muscle contraction or pain, and adjusted if required.
Study NCT03956407 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Repetitive peripheral nerve stimulation
Description: Sham repetitive peripheral nerve stimulation will be applied to the median nerve of the affected forearm with surface electrodes. The stimulator will be set to deliver bursts of 10 Hz stimulation at 50% duty cycle (500 ms on and off). For sham stimulation, intensities will be set at 10mv - 15mv lower than de lowest intensity able to induce sensory paraesthesias, and adjusted if required.
Study NCT01504984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYO-1126
Description: Imatinib 400mg/tablet, PO, 1 tablet once daily for I\&II D1(crossover)
Study NCT01504984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glivec film coated tab 4T(400mg)
Description: Imatinib 100mg/tablet, PO, 4 tablets once daily for period I\&II D1(crossover)
Study NCT01613430 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coach Training (COACH)
Description: Participants and their coaches receive Printed Educational Materials (PEM). Additionally, coaches will receive a 40-minute cancer-related training session led by a research staff member. The coaches will be provided basic information about different types of cancer screenings, how to schedule and keep medical visits, and how to communicate with health care providers about cancer screening. The session will be interactive, including short video presentations, role plays and exercises. Coaches will be given brochures on cancer screening for the three cancer types, a checklist for the coach and a Things to Remember diary checkup list, and resources addressing well-known barriers to cancer screening.
Study NCT01141478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: 400 mg po bid
Study NCT03478306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin 4 mg Tablet
Description: Participants are randomized into arm 1 or arm2, recieving melatonin or placebo, respectively, for 21 days, followed by 1 week of washout, and then swichting to the contralateral treatment arm.
Study NCT03478306 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Melatonin 4 mg Tablet
Description: Participants are randomized into arm 1 or arm2, recieving melatonin or placebo, respectively, for 21 days, followed by 1 week of washout, and then swichting to the contralateral treatment arm.
Study NCT03686345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midostaurin
Description: Midostaurin associated with standard chemotherapy in patients with core-binding factor leukemia
Study NCT01109979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol+MPA
Description: 1 single pill dose daily containing estradiol 1 mg + medroxyprogesterone acetate 2.5 mg
Study NCT01109979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol+Drospirenone
Description: 1 single pill dose daily containing estradiol 1mg + drospirenone 0.5 mg